✦ LIBER ✦

Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen

✍ Scribed by Nicolas Magné; Rémy Largillier; Pierre-Yves Marcy; Jacques Magné; Moïse Namer

Book ID: 106173470
Publisher: Springer-Verlag
Year: 2005
Tongue: English
Weight: 110 KB
Volume: 13
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-005-0804-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

p16INK4Aas a predictive factor in patien

p16INK4Aas a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy

✍ S Geisler, B Smith-Sørensen, D Betticher, IK Bukholm, LA Akslen… 📂 Article 📅 2000 🏛 BioMed Central 🌐 English ⚖ 298 KB

Cardioprotection with ICRF-187 (Cardioxa

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen

✍ Svetislav Jelić; Siniša Radulović; Zora Nešković-Konstantinović; Miroslav Kreači 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 743 KB

A study of cardioprotection with ICRF-187 (Cardioxane, Eurocetus) has been performed in 35 patients with metastatic breast cancer treated with the FDC regimen (5-fluorouracil 500 mg/m 2 i.v., day 1; doxorubicin 50 mg/m 2 i.v., day 1; cyclophosphamide 500 mg/ m 2 i.v., day 1). All patients had one or

Comparison of outcomes in high risk, loc

Comparison of outcomes in high risk, locally advanced and inflammatory breast cancer treated with high dose chemotherapy (Quartet) versus standard doxorubicin-based regimens

✍ O'Reilly, S.E.; Gelmon, K.; Tolcher, A. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Special focus on cardiac toxicity of dif

Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients

✍ Magné, Nicolas; Castadot, Pierre; Chargari, Cyrus; Di Leo, Angelo; Philippson, C 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 157 KB

PP-7-3 Epirubicin (E) plus paclitaxel (P

PP-7-3 Epirubicin (E) plus paclitaxel (P) in advanced breast cancer: A regimen with high activity and low cardiac toxicity which mobilizes peripheral blood stem cells

✍ P.F. Conte; A. Michelotti; E. Baldini; B. Salvadori; A. Gennari; C. Tibaldi; I. 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Doxorubicin-paclitaxel : A safe regimen

Doxorubicin-paclitaxel : A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial

✍ Laura Biganzoli; Tanja Cufer; Peter Bruning; Robert E. Coleman; Luc Duchateau; B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## BACKGROUND The potential cardiotoxicy of the doxorubicin‐paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies. ## METHODS In a large multicenter Phase III